Aripiprazole:: Pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia

被引：49

作者：

Gründer, G ^{[1
]}

Kungel, M ^{[1
]}

Ebrecht, M ^{[1
]}

Göröcs, T ^{[1
]}

Modell, S ^{[1
]}

机构：

[1] Rhein Westfal TH Aachen, Univ Klinikum Aachen, Klin Psychiat & Psychotherapy, D-52074 Aachen, Germany

来源：

PHARMACOPSYCHIATRY | 2006年 / 39卷

关键词：

D O I：

10.1055/s-2006-931485

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aripiprazole is the first approved atypical antipsychotic with a mechanism of action that exerts a partial agonism with high affinity at Dopamin D-2- and Serotonin-5-HT1A-receptors as well as an antagonism at Serotonin-5-HT2A-receptors. Aripiprazole provides good clinical effectiveness and a favorable profile of safety and tolerability. The special pharmacodynamics of aripiprazole are described herein.

引用

收藏

页码：S21 / S25

页数：5

相关论文

共 22 条

[11] SEROTONIN RECEPTORS IN THE HUMAN-BRAIN .1. CHARACTERIZATION AND AUTORADIOGRAPHIC LOCALIZATION OF 5-HT1A RECOGNITION SITES - APPARENT ABSENCE OF 5-HT1B RECOGNITION SITES [J].

HOYER, D ;

PAZOS, A ;

PROBST, A ;

PALACIOS, JM .

BRAIN RESEARCH, 1986, 376 (01) :85-96

[12] Molecular, pharmacological and functional diversity of 5-HT receptors [J].

Hoyer, D ;

Hannon, JP ;

Martin, GR .

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2002, 71 (04) :533-554

[13] Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder [J].

Kane, JM ;

Carson, WH ;

Saha, AR ;

McQuade, RD ;

Ingenito, GG ;

Zimbroff, DL ;

Ali, MW .

JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (09) :763-771

[14] Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia [J].

Kasper, S ;

Lerman, MN ;

McQuade, RD ;

Saha, A ;

Carson, WH ;

Ali, M ;

Archibald, D ;

Ingenito, G ;

Marcus, R ;

Pigott, T .

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2003, 6 (04) :325-337

[15] Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. [J].

Marder, SR ;

McQuade, RD ;

Stock, E ;

Kaplita, S ;

Marcus, R ;

Safferman, AZ ;

Saha, A ;

Ali, M ;

Iwamoto, T .

SCHIZOPHRENIA RESEARCH, 2003, 61 (2-3) :123-136

[16]

McQuade RD, 2002, INT J NEUROPSYCHOPH, V5, P176

[17] Serotonin receptors : their key role in drugs to treat schizophrenia [J].

Meltzer, HY ;

Li, Z ;

Kaneda, Y ;

Ichikawa, J .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2003, 27 (07) :1159-1172

[18]

Müller WE, 2002, PSYCHOPHARMAKOTHERAP, V9, P120

[19] Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study [J].

Pigott, TA ;

Carson, WH ;

Saha, AR ;

Torbeyns, AF ;

Stock, EG ;

Ingenito, GG .

JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (09) :1048-1056

[20] Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder [J].

Potkin, SG ;

Saha, AR ;

Kujawa, MJ ;

Carson, WH ;

Ali, M ;

Stock, E ;

Stringfellow, J ;

Ingenito, G ;

Marder, SR .

ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (07) :681-690